Margherita Neri is vector process development Director in AGC Biologics. She joined AGC, former MolMed, in 2012 working in the Quality Control Unit and then in Development Unit. She gained knowledge and experience in the design of vector production processes. She is involved in the process development and industrialization of large scale production of lentiviral and AAV vectors in compliance to GMP requirements.

She holds a degree in Pharmaceutical Biotechnology from Università degli Studi – Milano and a Ph.D. in molecular medicine with a study on gene therapy for lysosomal storage disorders.